Literature DB >> 17652978

[Computed tomographic atlas of benign asbestos related pathology].

C Beigelman-Aubry1, G Ferretti, D Mompoint, J Ameille, M Letourneux, J Frija, F Laurent.   

Abstract

The demonstration by computed tomography of abnormalities related to asbestos is essential for the recognition of industrial disease, the compensation of which has considerable economic consequences. The use of compute tomography, the most reliable technique for the detection of pleuro-parenchymatous abnormalities related to asbestos exposure, has increased considerably in France since the publication of the results of a consensus conference in Paris in 1999. Since that time, developments in technology have noticeably modified the protocols of investigation and increased the sensitivity of the detection of pleural and interstitial parenchymatous abnormalities and of nodules. The technical recommendations and those for the interpretation of pleural and parenchymatous abnormalities need to be well known. They are presented in the form of an atlas that gives detailed criteria for asbestosis, pleural plaques and pleural fibrosis. The diagnosis of pleural plaques depends on the combination of clear limits at the pleural and pulmonary interface, typical topography and multiple, bilateral localization. In the context of asbestos exposure the plaques are characteristic of this exposure, unlike diffuse pleural thickening, crow's feet images, parenchymatous bands and entrapped atalectasis. The writing of the radiological report would be most appropriate on this basis.

Entities:  

Mesh:

Year:  2007        PMID: 17652978     DOI: 10.1016/s0221-0363(07)89886-6

Source DB:  PubMed          Journal:  J Radiol        ISSN: 0221-0363


  1 in total

Review 1.  Focal pleural thickening mimicking pleural plaques on chest computed tomography: tips and tricks.

Authors:  Khalid M Alfudhili; David A Lynch; Francois Laurent; Gilbert R Ferretti; Vincent Dunet; Catherine Beigelman-Aubry
Journal:  Br J Radiol       Date:  2015-11-05       Impact factor: 3.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.